Watson’s Global Brands business includes more than 30 brand products, primarily sold in the U.S. The division is focused on leadership in Urology and Women’s Health. Net revenues in our Global Brands segment accounted for approximately $398 million or approximately 11% of our total net revenues in 2010. Typically, our brand products realize higher profit margins than our generic products.

During 2010, we launched Crinone® (progesterone gel), ella® (ulipristal acetate), and Trelstar® (triptorelin pamoate) 22.5 mg. Crinone was acquired from Columbia Laboratories, Inc. ("Columbia") and is currently used for progesterone supplementation or replacement as part of an Assisted Reproductive Technology treatment for infertile women with a progesterone deficiency, as well as the treatment of secondary amenorrhea. ella is an emergency contraceptive proven effective in helping prevent pregnancies for up to five days after unprotected intercourse or contraceptive failure. Trelstar 22.5 mg is a 6-month intramuscular GnRH agonist for the palliative treatment of advanced prostate cancer.

Global Brands 2010 Business Highlights

• Focused on expansion within key therapeutic categories in Urology and Women’s Health
• 30+ pharmaceutical product families in U.S. portfolio
• Generated approximately $398 million in Brand Revenues
• Launched three new products: Trelstar® 22.5mg, Crinone®, ella®
• In-licensed Esmya™ ulipristal acetate: uterine fibroids
• In-licensed first biologic – recombinant Follicle Stimulating Hormone (rFSH): Infertility
• Significant progress in expanding Global Brands Business into Canada and Latin America

Brand Sales & Marketing

We market our brand products through approximately 350 sales professionals. Our sales and marketing efforts focus on physicians, specifically urologists and OB/GYNs, who specialize in the diagnosis and treatment of particular medical conditions and each group offers products to satisfy the unique needs of these physicians. Approximately 60 of these sales professionals are strategic account specialists who focus on institutions and clinics. We believe this focused sales and marketing approach enables us to foster close professional relationships with specialty physicians, as well as cover the primary care physicians who also prescribe in selected therapeutic areas. We generally sell our brand products under the "Watson Pharma" label. We believe that the current structure of sales professionals is very adaptable to the additional products we plan to add to our brand portfolio, particularly in the therapeutic category of Women's Health.